Meixi Hao

机构：China Pharmaceutical University, State Key Laboratory of Natural Medicine · ORCID：0000-0002-2049-2220

发表论文 17 篇 · 总被引 497 次 · h-index 10

代表论文

• Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy (2020 · Science Translational Medicine · 被引 180)
• Sensitizing Tumors to Immune Checkpoint Blockage via STING Agonists Delivered by Tumor-Penetrating Neutrophil Cytopharmaceuticals (2023 · ACS Nano · 被引 76)
• Cytopharmaceuticals: An emerging paradigm for drug delivery (2020 · Journal of Controlled Release · 被引 51)
• Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages (2024 · ACS Nano · 被引 35)
• Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment (2020 · Journal of Medicinal Chemistry · 被引 34)
• An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy (2022 · Advanced Drug Delivery Reviews · 被引 23)